Rituximab after transplantation in mantle and large cell lymphoma – pro
Rituximab, a monoclonal antibody targeting CD20, has shown a good safety profile and high efficiency in patients with various B-cell lymphomas. Prospective trials have investigated maintenance therapy with rituximab. The European Mantle Cell Lymphoma Network found that among elderly patients who had an initial response to R-CHOP, rituximab maintenance therapy until disease progression prolonged both progression-free survival and overall survival. Other studies confirmed these findings in younger patients with Mantel Cell lymphoma as well. However, these findings had not been replicated in large cell lymphomas.
Steven Le Gouill, Catherine Thieblemont, Lucie Oberic, Anne Moreau, Krimo Bouabdallah, Emmanuel Gyan, Gandhi Damaj, Vincent Ribrag, Pierre Feugier, Olivier Casasnovas, Hacene Zerazhi, Corinne Haioun, Hervé Tilly, Olivier Tournilhac, Herve Maisonneuve, Philippe Solal-Celigny, Luc Mathieu Fornecker, Eric W Van Den Neste, Danielle Canioni, Gilles Salles, Thierry Lamy, Marie-Christine Bene, Remy Gressin and Olivier Hermine, Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. Blood 2016 128:145
Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462-9.
NCCN, V-cell large cell lympma, 2018